Novacyt share price: should I buy the dip?

The Novacyt share price has fallen 40% in one month. Roland Head asks if it’s time to start buying despite uncertainty about post-Covid profits.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The Novacyt SA (LSE: NCYT) share price hit a high of 1,190p in January, but it’s fallen sharply since. As I write, the shares are trading at around 700p, meaning this biotech stock has dropped 40% in just one month.

That’s a painful decline, but I think it’s worth keeping in context. Novacyt shares are still worth 400% more than they were one year ago, thanks to the success of its Covid-19 testing kits. These were developed rapidly at the start of the pandemic to meet surging demand.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

An update today has confirmed the company is continuing to develop its Covid-19 product portfolio. However, we’ll have to wait until the second quarter of this year to learn more about Novacyt’s long-term plans.

For this reason, I think it’s fair to say there’s not much visibility on earnings once demand for Covid-19 products starts falling. As a potential investor, this is obviously a key risk. But I think it’s also an opportunity. If Novacyt can maintain its success, I believe it could become a more valuable business.

What happens after Covid-19?

The story so far is impressive. Novacyt’s sales rose from £11.5m in 2019 to £277m in 2020. Profits rose too. The company expects to report cash earnings before various costs of £187m for 2020. I’m not surprised Novacyt’s share price performed so well last year.

CEO Graham Mullis deserves full credit for his company’s impressive performance, in my view. But he still faces the challenge of making sure Novacyt’s newfound profitability doesn’t disappear when demand for Covid-19 products falls. Remember, until 2020, Novacyt had reported a loss every year since its flotation in 2012.

Mullis’ aim is to build “a sustainable, long-term diagnostics business.” One potential opportunity is Versalab, which aims to support private sector testing for infectious diseases. This service was launched in November 2020. It’s initially focused on Covid-19, but further tests are planned.

Novacyt share price: why I don’t think it’s cheap

Based on Novacyt’s expected earnings for 2020, the shares trade on about three times earnings. In my experience, when a company’s stock is rated this cheaply it means the market expects profits to fall.

That’s my view too. The company expects sales of Covid-19 products to be “strong throughout most of 2021.” But there’s little visibility beyond that.

This uncertainty is reflected in the latest forecasts from Novacyt’s house broker, which are available on its website. Earnings are expected to fall by around 17% in 2021, before dropping by around 65% in 2022.

Based on these forecasts, Novacyt’s current share price values the stock on about 12 times 2022 forecast earnings. That seems reasonable to me. But with no visibility on future earnings, it’s not cheap enough to persuade me to buy.

Novacyt’s technology has been a huge commercial and medical success during the pandemic. But without specialist medical knowledge, I’m not sure I can estimate how easily the firm’s will be able to expand into new areas.

For me, investing in a stock like this is too speculative. I won’t be buying, despite the possibility that Novacyt shares might be cheap today.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

2 undervalued passive income stocks I’d buy today with £1,000

Falling stock prices are pushing up dividend yields. As a result, our author is looking for undervalued passive income stocks…

Read more »

Close-up of British bank notes
Investing Articles

2 cheap dividend shares I’d buy in a heartbeat

Our writer picks a pair of FTSE 100 dividend shares he would consider for his portfolio, that he thinks look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

With £500, I’d use the Warren Buffett method to find cheap shares

The legendary investor Warren Buffett has become a billionaire by following some key investment principles. Our writer explains why he…

Read more »

Man in a clothing store in a medical mask because of a coronovirus.
Investing Articles

Down 81%, are boohoo shares set for an explosive comeback?

boohoo shares have been falling rapidly. But could interest from a billion-dollar hedge fund cause a turnaround in 2022?

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

The Tullow Oil (TLW) share price jumps after losses! Is now the time to buy?

The Tullow Oil (TLW) share price ticked upwards on Thursday morning after falling nearly 30% over the last month. So,…

Read more »

Female analyst sat at desk looking at pie charts on paper
Investing Articles

Is the Lloyds share price about to dip below 40p?

The Lloyds share price has been trading below 50p for the better part of the year. But could the stock…

Read more »

Cheerful young businesspeople with laptop working in office
Investing Articles

2 beaten-down FTSE 250 shares I’m buying and holding for the long term

Andrew Woods explains why he's adding two FTSE 250 shares to his portfolio in the middle of a market sell-off.

Read more »

Female analyst sat at desk looking at pie charts on paper
Investing Articles

The Legal & General (LGEN) share price jumps 3%! Am I too late to buy?

The Legal & General (LGEN) share price soared in early trading on Thursday as the company registered a good start…

Read more »